Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Received at least 2 and no more than 3 monthly Lucentis or Avastin injections~* Last Lucentis or Avastin was injected approximately 4 weeks prior to screening~* Visual acuity between 20/320 and 20/40~Exclusion Criteria:~* Active ocular infection~* Contraindication to pupil dilation in either eye~* Eye surgery including cataract surgery and/or laser of any type within 3 months

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 700 ug dexamethasone and ranibizumab (Type: EXPERIMENTAL): Intravitreal injection of 700 ug dexamethasone and ranibizumab into study eye
- ranibizumab and sham (Type: ACTIVE_COMPARATOR): Intravitreal injection of ranibizumab and Sham into study eye

Based on this trial design, predict the completion outcome and termination type (if applicable).